• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TLX 1.49% $26.49

TELIX PHARMACEUTICALS LIMITED - Charts / Financials

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company... Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.More

refresh Created with Sketch. REFRESH
Day
Open $26.42   Day High $26.57   Day Low $26.12
Daily Volume 667731
Bids   Sellers
Number Price Volume   Number Price Volume
1 $26.35 2   2 $26.50 3604

Directors & Senior Management

Dr. Christian P. Behrenbruch Group Chief Executive Officer, Managing Director, Executive Director
Mr. Darren Smith Group Chief Financial Officer
Mr. Raphael Ortiz Chief Executive Officer - APAC and EMEA
Mr. Kevin Richardson Chief Executive Officer, Americas
Dr. Darren Patti Group Chief Operating Officer
Ms. Lena Moran - Adams Group General Counsel
Dr. David Cade Group Chief Medical Officer
Mr. James Stonecypher Group Chief Development Officer
Mr. Richard Valeix Group Chief Commercial Officer
Ms. Genevieve Ryan Company Secretary
Mr. H. Kevin Mccann Non-Executive Independent Chairman of the Board
Dr. Mark Nelson Non-Executive Independent Director
Ms. Tiffany P. Olson Non-Executive Independent Director
Ms. Jann Skinner Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$26.49
Change
0.390(1.49%)
Mkt cap ! $8.866B
Open High Low Value Volume
$26.42 $26.57 $26.12 $17.65M 667.7K

Buyers (Bids)

No. Vol. Price($)
1 2 $26.35
 

Sellers (Offers)

Price($) Vol. No.
$26.50 3604 2
View Market Depth
Last trade - 16.10pm 21/01/2025 (20 minute delay) ?
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.